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ABSTRACT
Objective: This study aimed to obtain an optimal and validated method of analyzing 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) simultaneously 
in dried blood spot samples using ultra high-performance liquid chromatography-tandem mass spectrometry.
Method: Separation was performed with a 1.7-μm amide column, which had a mobile phase with a flow rate of 0.2 mL/min and comprised 0.2% 
formic acid in water, 0.1% formic acid in acetonitrile, and methanol with a gradient elution. Detection was performed using Waters Xevo TQD.
Result: This method was linear with a range of 25–1000 ng/mL for 6-MP and 6-TG, with consecutive r values of ≥0.996 and ≥0.995, respectively. The 
intra- and inter-day % difference value and coefficient of variation for the accuracy and precision were not more than 15% and 20%, respectively, at 
a concentration lower limit of quantitation.
Conclusion: This method fulfilled the requirements of the European Medicines Agency guideline for validation.
Keywords: 6-Mercaptopurine, 6-Thioguanine, Dried blood spot, Ultra-high-performance liquid chromatography-tandem mass spectrometry.
INTRODUCTION
Leukemia is a disease that affects the blood and blood-forming tissues 
in the bone marrow of the spinal cord [1]. In patients with leukemia, 
the spinal cord produces abnormal white blood cells, which are called 
leukemia that will continuously produce cells to disrupt normal blood 
cells [2]. In 2010, a total of 43,000 men and women in the United States 
were diagnosed with leukemia, and 21,840 of them died. Leukemia 
accounts for 33% of the cancer incidence in children and kills 1340 
children per year. Leukemia is divided into acute lymphocytic leukemia 
(ALL), acute non-lymphocytic leukemia, acute myelocytic leukemia 
(AML), and chronic myelocytic leukemia; among these, the acute types 
account for the highest prevalence of 97% (82% ALL and 18% AML) [3]. 
One of the curative treatments for ALL is chemotherapy [4].
6-mercaptopurine (6-MP) is an antimetabolite drug that is often used for 
cancer chemotherapy, especially in ALL, in both children and adults [5]. 
6-MP undergoes three metabolic pathways. In the first pathway, 
mercaptopurine is transformed into thioinosine monophosphate 
by the enzyme hypoxanthine phosphoribosyl transferase and is 
subsequently converted to its active metabolite 6-thioguanine (TG) 
nucleotide, which is easily hydrolyzed into 6-TG. In the second 
pathway, 6-MP is be hydroxylated by xanthine oxidase to an inactive 
metabolite 6-thiouric acid. The final 6-MP pathway involves methylation 
to 6-methylmercaptopurine (6-MMP) by thiopurine methyltransferase 
(TPMT) [6]. High concentrations of 6-TG have been found to correlate 
with therapeutic efficacy, and high 6-MMP concentrations were 
associated with liver toxicity [7]. Since the metabolite formation of 6-MP 
is affected by TPMT enzymes that undergo polymorphism, the effects of 
6-MP treatment vary widely among individuals. Therefore, monitoring 
the efficacy of a therapeutic drug regimen becomes important in ALL.
One method for monitoring drug therapy is analyzing the drug and 
its metabolites in biological samples, such as blood, plasma, urine, 
and saliva [8]. One of the biosampling methods for monitoring drug 
therapy is dried blood spot (DBS) or dry blood sample on paper. The 
DBS method entails collection of blood from the human body, usually 
from the fingers or heels, followed by spotting of the sample on a 
special paper until the blood becomes dry for immediate analysis or 
storage. This method has several advantages. First, the solid form of 
DBS makes the analyte less reactive than that in the liquid form. This 
will increase the stability even if it is not stored in a cold environment, 
unlike other matrices. This method also has the advantage of being 
minimally invasive to the patient because the collection of blood uses 
only sterile lancet needles. Another advantage is the small volume of 
required blood sample, which is usually 10–80 μL [9].
Several analysis methods of 6-MP and 6-TG in whole blood or plasma 
have been done before; ultra-high-performance liquid chromatography-
tandem mass spectrometry (UPLC-MS/MS) had been used to analyze 
both 6-MP and 6-TG in plasma samples [7] and 6-MP metabolites in 
whole blood samples [10]. On the other hand, a method for analysis of 
dry blood is still not available.
Although the DBS method has many advantages, it also has some limitations, 
such as the small volume of blood used, which would require a selective 
and sensitive method of analysis. For such purpose, the UPLC-MS/MS 
can be used, with 6-MP, 6-TG, and 5-fluorouracil (5-FU) as the internal 
standards. The advantage of using UPLC-MS/MS is rapid analysis, as well 
as the selectivity and high sensitivity for detecting the test substance [8].
To date, a validated method of analyzing 6-MP and 6-TG in DBS using 
UPLC-MS/MS remains unavailable. Therefore, this study aimed to 
obtain and validate a method of bioanalysis of DBS using UPLC-MS/MS, 
with 6-MP, 6-TG, and 5-FU as internal standards. The optimum method 
will be validated to meet the requirements listed in the European 
Medicine Agency 2011. This method is expected to be applied for 
monitoring 6-MP drug therapy in pediatric patients with ALL.
MATERIALS AND METHODS
Materials
The reagents included 6-MP (Sigma-Aldrich), 6-TG (Sigma-Aldrich), 
5-FU (Sigma-Aldrich), HPLC-grade acetonitrile (Merck), HPLC-grade 
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methanol (Merck), and formic acid (Merck). The other materials used 
were ultrapure water (Sartorius Water Filter), CAMAG DBS paper, and 
blood samples (Palang Merah Indonesia).
Instruments
UPLC-MS/MS (Waters Xevo TQD Triple Quadrupole) comprised 
quaternary solvent manager (Acquity UPLC H-Class); sample manager 
(Acquity UPLC); nitrogen generator compressor (PEAK Scientific); 
an amide acquity UPLC BEH Column (100 mm × 2.1 mm; 1.7-μm); 
mass analyzer in the form of triple quadrupole (Xevo TQD) with 
ionization source (ZsprayTM); data processing software (MassLynx 
Software) and computer (Lenovo); analytical scales (AND); ultrasonic 
stirrer (Elmasonic); 4°C refrigerators; gas bleach (Elmasonic S40H); 
vortex (Maxi Mix II); centrifugator (Digisystem DSC-300SD); freezer 
temperature at −20°C (Biomedical Labtech Deep Freezer); evaporator 
(TurboVap LV); sample tubes (Falcon); Eppendorf micropipes 
(Soccorex); blue tip; yellow tip; and glassware.
Stock solution
The standard compounds 6-MP, 6-TG, and 5-FU, which were carefully 
weighed to a maximum of 5.0 mg each, were placed into a 5.0-mL 
measuring flask. Each substance was dissolved in 1N NH4OH to make 
a 2-mL solution; this was followed by addition of methanol to fill in the 
entire measuring flask. The standard compound solution obtained had 
a concentration of 1.0 mg/mL and was diluted accordingly to obtain a 
certain concentration. The solution was stored at 4°C until analysis.
Preparation of DBS samples
The DBS samples were placed on paper containing 6-MP and 6-TG at 
certain concentrations. The paper was then cut into 8-mm pieces, which 
were placed into 15-mL tubes with methanol to extract as much as 4 mL 
of solution. Thereafter, the solution was mixed with a vortex for 2 min, 
followed by sonication at 40°C for 20 min and centrifugation for 10 min 
at 3100 rpm. The supernatant was collected and placed into a test tube 
before making it evaporate to dry for 30 min at 40°C with the use of 
N2 gas. The obtained residue was then reconstituted with 100-μL 50% 
acetonitrile-water; the solution was mixed with a vortex for 2 min and 
underwent sonication for 2 min before it was transferred into the vial 
insert. After centrifugation of the solution at 3100 rpm for 5 min, as much 
as 5 µL of the final solution was injected into the UPLC-MS/MS system.
System suitability test
As much as 5 μL of a mixture containing 1000 ng/mL of 6-MP and 6-TG 
with 100 μg/mL of 5-FU was injected into UPLC-MS/MS at a selected 
mobile phase, flow rate, and solvent. The injection was repeated 5 times. 
The coefficient of variation, ratio of peak area, and retention time of the 
analyte and internal standard were determined. System suitability test 
was defined to have qualified if the coefficient of variation was lower 
than 5%.
Chromatography condition
Chromatography was performed using an amide column (100 × 
2.1 mm; 1.7 μm) aquity UPLC BEH. The analysis was performed in a 
mobile phase, with elution gradient conditions as shown in Table 1.
The flow rate used was 0.2 mL/min at a temperature of 25°C. Mass 
detection was performed using Waters Xevo TQD with positive 
electrospray ionization (ESI) for 6-MP and 6-TG and negative ESI for 
5-FU in multiple reaction monitoring mode. Detection of 6-MP, 6-TG, 
and 5-FU was 153.09>119.09, 168.09>107.06, and 129.15>42.05, 
respectively.
Validation of analysis methods
Lower quantitation limit determination
Five replicas were made using 25 ng/mL of 6-MP and 6-TG 
concentrations spotted on a DBS paper. The DBS sample preparation 
was performed at selected optimum conditions. A total of 5 μL of the 
final solution was injected into the UPLC-MS/MS system under selected 
chromatographic conditions. The values of % diff and % CV, with 
requirements not exceeding ± 20%, were calculated.
Linearity of calibration curve
The following were prepared: (1) A blank sample (whole blood on a 
DBS paper without an internal standard); (2) one zero sample (blood 
on a DBS paper with an internal standard); and (3) non-zero samples 
of analytes, including lower limit of quantitation (LLOQ), with 6-MP at 
concentrations of 25, 50, 100, 200, 500, 800, and 1000 ng/mL and 6-TG 
at concentrations of 25, 50, 100, 200, 500, 800, and 1000 ng/mL. The 
concentration of each calibration curve was spotted on the DBS paper, 
which was cut into pieces and placed in a container with 100 μL of the 
internal standard 5-FU at a concentration of 100 μg/mL. Thereafter, 
as much as 5 μL of each solution was extracted and injected into the 
UPLC-MS/MS. The correlation coefficient of the linear regression 
equation was calculated to determine the linearity of the curve. In 
addition, the % diff was calculated with a limit value not exceeding 
±15% for all concentration levels, except for LLOQ, which had a limit 
value of not exceeding ±20%.
Selectivity
A 40-μL whole blood blank was prepared and sample preparation was 
performed. Under selected conditions, as much as 5 μL of the final 
solution was injected into the UPLC-MS/MS system. Tests on this blank 
sample were done in duplicate using six blood samples collected from 
different sources. Next, blood containing a standard solution of 6-MP 
and 6-TG was prepared at LLOQ concentration; as much as 5 μL of the 
final solution was injected into the UPLC-MS/MS system. Testing of the 
LLOQ concentration was done in duplicate using six blood samples 
collected from different sources. The analyte and the standard were 
simultaneously observed for retention time and any interference from 
the blood extract; the response obtained was not >20% in the LLOQ 
analytes and not >5% in the internal standard.
Carryover
Carryover was performed by preparing the blank of DBS, and samples 
were prepared according to sample preparation conditions. The final 
solution was injected into the UPLC-MS/MS system after injecting the 
standard solution which contained 6-MP and 6-TG at the concentration 
of the upper limit of quantitation. Peak area of 6-MP, 6-TG, and the 
internal standard that appeared from the blank was observed. This test 
was replicated 5 times.
Accuracy and precision
Blank blood samples were mixed with a working solution at LLOQ 
concentration and a control solution at low-quality concentration 
(QCL), medium concentration, and high concentration (QCH) solution. 
Each mixture was added the internal standard with a concentration 
of 100-μg/mL and extracted according to the sample preparation 
procedure. Then, 5 μL of the final solution was injected into the 
UPLC-MS/MS system. This test was repeated for 5 times within the 
day (within-run) and between days (between-run). The % diff was 
calculated as the accuracy parameter and % CV was calculated as the 
precision parameter. The values of % diff and CV did not exceed ± 15% 
for each concentration, except at LLOQ concentrations (i.e., not 
exceeding ±20%).
Table 1: Mobile phase elution profile






0.0 85 5 10
2.0 25 65 10
3.0 5 85 10
4.0 85 5 10
5.0 85 5 10
aMobile phase A=(Formic acid 0.2% in water solution), bmobile phase 
B=(formic acid 0.1% in acetonitrile solution), cmethanol
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Dilution integrity
A blood sample solution containing 6-MP and 6-TG at 2000 ng/mL, 
which was twice as the concentration of QCH, was prepared. Then, it 
was diluted with blank blood to get half and quarter concentrations. 
The diluted samples were prepared accordingly, and as much as 5 μL of 
the final solution was injected into the UPLC-MS/MS system. The test 
was repeated 5 times, and the corresponding parameters of accuracy 
and precision were determined.
Matrix effect
A total of 40 μL of blood blank was prepared and sample preparation 
process was done as described above. The supernatant was then 
mixed with 6-MP and 6-TG at QCL and QCH, as well as internal 
standard with a concentration of 100 μg/mL. A total of 5 μL of 
the final solution was injected into the UPLC-MS/MS system. The 
matrix effect was determined by calculating the matrix factor (MF), 
which was the ratio of area 6-MP, 6-TG, and internal standard after 
extraction compare to area of 6-MP, 6-TG, and internal standard 
without extraction or in solution. The normalized internal standard 
MF was calculated by dividing the analytic MF by the internal 
standard MF. Calculation of the %CV obtained did not exceed ±15% 
for each concentration.
Stability
Stability of the stock solution
The stock solution of 6-MP, 6-TG, and internal standard was prepared 
in a concentration of 1000 μg/mL. As much as 5 μL of each solution 
was injected into the UPLC-MS/MS system and then was stored at room 
temperature for 0, 6, and 24 h before analysis.
Short-term stability
DBS samples of 6-MP and 6-TG at QCL and QCH were prepared and 
stored at room temperature for 0, 6, and 24 h. The internal standard 
solution was added to the extracted solution, followed by sample 
preparation. A total of 5 µL of the solution was injected into the 
UPLC-MS/MS system. The instability of the substance was observed by 
calculating the % diff and shape of each chromatogram. The test was 
performed thrice for each concentration.
Long-term stability
DBS with 6-MP and 6-TG of QCL and QCH were prepared and stored 
at room temperature for 30 days. The internal standard was added 
to the extracted solution, followed by sample preparation. A total of 
5 μL of the solution was injected into the UPLC-MS/MS system. The 
instability of the substance was observed by calculating the % diff and 
shape of each chromatogram. The test was performed thrice for each 
concentration.
Autosampler stability
DBS samples of 6-MP and 6-TG at QCL and QCH were prepared, injected, 
and left on the autosampler vials for 24 h. Analyses were done on the 
0-h and 24-h time points. A total of 10 μL of the solution was injected 
into the UPLC-MS/MS system. The instability of the substance was 
observed by calculating the % diff and shape of each chromatogram. 
The test was performed thrice for each concentration.
RESULTS AND DISCUSSION
Test system sustainability
The CV values obtained were <2.0% in the area and in the retention 
time of each analyte area. The analysis time for each injection was 5 min.
The LLOQ
The LLOQ of 6-MP was determined as 25 ng/mL, with a % diff 
value of −12.83–14.39% and %CV of 11.32%; these values met the 
requirements. When the LLOQ was decreased to half at 12.5 ng/mL, the 
obtained % diff of −212.00–187.53% and %CV of −12.32% did not meet 
the requirement of % diff of <20% to obtain an LLOQ concentration 
for 6-MP of 25 ng/mL. Meanwhile, the 25-ng/mL LLOQ value for 6-TG 
rendered a % diff value of −14.85–9.30% and % CV of 11.93%; these 
values met the requirements. When the LLOQ was decreased to half 
at 12.5 ng/mL, the obtained % diff of −149.30–137.57% and %CV of 
−36.43% did not meet the requirement of % diff of <20% to obtain the 
desired LLOQ concentration for 6-TG.
The calibration curves
The calibration curve of 6-MP yielded linear regression equation of 
y=0.5789+0.0193x, with r=0.9981
Where x represented the 6-MP concentration (ng/mL) and y represented 
the peak area ratio between 6-MP and the internal standard 5-FU.
The 6-TG calibration curve yielded a linear regression equation 
y=0.4307+0.0222x, with r=0.9964
The value of CV ranged from 0.67% to 12.84% (average r=0.9977) for 
6-MP and from 0.66% to 9.94% (average r=0.9966) for 6-TG.
Accuracy and precision
Within-run measurement of the accuracy of 6-MP obtained a 
% diff value that ranged from −12.58% to + 14.00% for LLOQ 
concentration and −10.66% to + 12.63% for QC concentrations. 
Within-run measurement of the precision of 6-MP obtained CV 
values of 10.82% for LLOQ concentration and <9.70% for QC. 
Within-run measurement of the accuracy of 6-TG obtained a % diff 
value that ranged from −17.79% to + 9.76% for LLOQ concentration 
and −6.22% s.d. + 11.84% for QC concentrations. Within-run 
measurement of the precision of 6-TG obtained CV values of 13.25% 
for LLOQ concentration and <6.99% for QC. From the results 
obtained, the within-run tests for accuracy and precision of both 
analytes qualified for the % CV and % diff values of below 20% for 
LLOQ and below 15% for QC.
Between-run measurement of the accuracy of 6-MP obtained a % diff 
value that ranged from −15.48% to + 17.81% for LLOQ concentration 
and −12.87% to + 12.63% for QC concentrations. Between-run 
measurement of the precision of 6-MP obtained % CV values of 10.93% 
for LLOQ concentration and <8.32% for QC. The % diff and % CV 
values in both the between-run measurements met the accuracy and 
precision requirements. Between-run measurement of the accuracy of 
6-TG obtained a % diff value that ranged from −18.61% to + 13.52% for 
LLOQ concentration and −13.20% to + 11.84% for QC concentrations. 
Between-run measurement of the precision of 6-MP obtained CV values 
of 13.25% for LLOQ concentration and <6.99% for QC. The % diff and 
% CV values in both between-run measurements met the accuracy and 
precision requirements.
Accuracy, which was represented by the value of % diff, was a parameter 
that measured the proximity between the measured concentrations 
in the analysis and the actual concentration; on the other hand, 
precision was a parameter that measured the repeatability of the 
analyte measurement. The accuracy and precision tests performed on 
both analytes for either the within- or between-run measures met the 
requirements set forth in the EMEA.
Selectivity
The results showed that the interference at LLOQ concentration was 
7.81–14.22% for 6-MP; 1.49–6.91% for 6-TG; and 1.38–4.91% for the 
internal standard.
Carryover
The carryover yield was 7.46–15.02% for 6-MP; 0.48% s.d. 8.66% for 
6-TG; and 1.89–4.66% for the internal standard.
Dilution integrity
The results of the dilution integrity test for 6-MP met the requirements, 
with % diff and % CV values of −6.73–3.85% and 4.45%, respectively, 
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for half-dilution, and −7.98–4.38% and 5.28%, respectively, for quarter 
dilution. Likewise, the results of the dilution integrity test for 6-TG met 
the requirements, with % diff and % CV values of −1.19–5.19% and 
2.56%, respectively, for half-dilution, and −12.31–6.32% and 7.72%, 
respectively, for quarter dilution.
Test of matrix effects
In this study, the average MF and % CV for 6-MP were 0.76% and 8.89%, 
respectively, at a QCL concentration and 0.81% and 7.01%, respectively, 
at a QCH concentration. The average MF and % CV for 6-TG were 0.79% 
and 7.71%, respectively, at QCL concentration and 0.77% and 3.58%, 
respectively, at QCH concentration. The results obtained showed 
matrix values of <1, which indicated that there was suppression of the 
ion. The mechanism of ionizing or ion enhancement in UPLC-MS/MS 
depends on the sample matrix, sample preparation, and ionization type. 
ESI was more susceptible to the matrix effects than to the APCI. The 
most influential factors in the suppression or enhancement of ions in 
bioanalysis are the biological matrix and the extraction method [11-14]. 
The % CV values of both analytes met the EMEA-specific requirements 
(i.e., the % CV obtained from six different blood sources does not 
exceed 15%).
Stability test
Stability of the stock solution
The % diff and % CV values of the stock solutions at room temperature 
for 24 h were −2.00–1.96% and 0.03%, respectively, for 6-MP; 
−1.03−0.80% and 0.17%, respectively, for 6-TG; and −0.2% and 0.39%, 
respectively, for the internal standard. The data above fulfilled the 
requirements of % diff and % CV not exceeding ± 5%. Therefore, it 
can be concluded that all the stock solutions of both analytes and the 
internal standard were stable at room temperature for 24 h. In addition 
to testing at room temperature, stability test of the stock solution was 
performed at −20°C for 20 days. The long-term stability test results 
showed % diff and % CV values at −0.74–0.40% and 0.24%, respectively, 
for 6-MP, and −0.50%–0.12% and 0.27%, respectively, for 6-TG; and a % 
diff of −1.98–1.56% for the internal standard. From these data on long-
term stability of the stock solution, we concluded that the stock solution 
remained stable for 20 days at −20°C.
Short-term stability
The results of the short-term stability test for 6-MP obtained % diff 
values of −6.58–8.94% at QCL and −12.50–3.73% at QCH. The results 
of the short-term stability test for 6-TG obtained % diff values of 
−6.74–9.63% at QCL and −12.94–9.94% at QCH. All the % diff values 
for both 6-MP and 6-TG were below 15%; therefore, it can be concluded 
that the analyte will be stable on DBS paper that has been dried for 24 h.
Long-term stability
From the results of the research, the values of % diff for both 6-MP at 
QCL (6.93–9.08%) and QCH (10.49–12.58%) and 6-TG at QCL (−1.69–
3.71%) and QCH (1.49–8.03%) remained stable until the 16th day. 
Therefore, it can be concluded that 6-MP and 6-TG can remain stable in 
DBS for up to a minimum of 16 days.
Post-preparation stability (autosampler)
The results of the stability tests of the sample in autosampler obtained 
% diff values of −5.66–10.95% at QCL and −4.29–3.92% at QCH for 
6-MP and −7.24–6.07% at QCL and −8.60–−1.83% at QCH for 6-TG. All 
the % diff values from both 6-MP and 6-TG were below 15%. Therefore, 
both can be deemed as stable solutions for storage in an autosampler 
for 24 h.
CONCLUSION
The developed UPLC-MS/MS method was useful and optimal for 
the determination of 6-MP and 6-TG in DBS using 5-FU as internal 
standard. These methods fulfilled the validation requirements of the 
EMEA bioanalytical guideline of 2011; met the linearity criteria of 
the calibration curve, LLOQ, accuracy and precision, dilution integrity, 
selectivity, carry over, stability and matrix effects; and can be applied to 
in vivo studies.
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